Eli Lilly vs Structure Therapeutics: Revenue Comparison
Eli Lilly (LLY) and Structure Therapeutics (GPCR) are peers in GLP-1. Eli Lilly reported revenue of $19.8B as of Q1 2026, compared with $0 for Structure Therapeutics. Eli Lilly leads on revenue.
Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q1 2026: Eli Lilly 19.799, Structure Therapeutics 0.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Eli Lilly, Structure Therapeutics.| Metric | Eli Lilly | Structure Therapeutics |
|---|---|---|
| Market Cap | - | - |
| Revenue | $19.80B | $0 |
| Cost of Revenue | $3.58B | $1.00M |
| Gross Profit | $16.22B | $-1.00M |
| Operating Income | $8.85B | $-90.00M |
| Net Income | $7.40B | $-76.00M |
| R&D Expense | $3.51B | $67.00M |
| Earnings Per Share | $8.26 | -$1.05 |
| Gross Margin | 81.9% | - |
| Operating Margin | 44.7% | - |
| Net Profit Margin | 37.4% | - |
| Free Cash Flow | $3.01B | $14.00M |
| Cumulative Free Cash Flow | $101.90B | $-469.00M |
| Operating Cash Flow | $5.33B | $15.00M |
| Cash & Equivalents | $5.14B | $316.00M |